Estimated Reading Time: 8 minutes
Most men who come to LiteWell asking about testosterone already know something is off. The fatigue is real. The mental fog is real. The changes in body composition, motivation, and drive are real. What they often don’t know—and what standard medical care frequently fails to explain—is why their testosterone is low.
The answer matters more than most people realize.
Low testosterone is not a single diagnosis. It is a symptom with distinct underlying causes, and those causes fall into two fundamentally different categories: primary hypogonadism and secondary hypogonadism. The distinction isn’t just academic. It changes the diagnostic workup, the treatment approach, the likelihood of restoring natural hormone production, and—for men who want children—whether fertility is even on the table.
This article explains both types in plain language, how your physician differentiates between them, and what the difference means for your care at LiteWell.
Key Takeaways
- Low testosterone (hypogonadism) has two fundamentally different causes: problems with the testes themselves (primary) or problems with the brain’s signaling system (secondary).
- Primary hypogonadism means the testes are not responding to hormonal signals; secondary means the signals are not being sent properly.
- Two lab values — LH and FSH — distinguish between the two types and are essential to any complete testosterone workup.
- Secondary hypogonadism is often reversible when the underlying cause is identified and addressed.
- For men who want to preserve or restore fertility, secondary hypogonadism responds to stimulation therapies that primary hypogonadism typically does not.
- A diagnosis based solely on total testosterone without LH and FSH is incomplete.
- At LiteWell, treatment is built around the full clinical picture — not just the number on a lab report.
Table of Contents
- What Is Hypogonadism?
- The HPG Axis: Understanding the Body’s Testosterone Signaling System
- Primary Hypogonadism: When the Problem Is in the Testes
- Secondary Hypogonadism: When the Problem Is in the Brain’s Signaling
- How Physicians Differentiate Between the Two
- Why the Distinction Matters for Treatment
- Myths vs. Facts
- LiteWell’s Clinical Approach
- Frequently Asked Questions
- Related LiteWell Services
- Related Insights
- References
- Medical Disclaimer
What Is Hypogonadism?
Hypogonadism refers to a clinical syndrome characterized by insufficient testosterone production. In men, this manifests as a combination of symptoms — fatigue, reduced libido, cognitive changes, mood shifts, loss of muscle mass, increased body fat, and in some cases, sexual dysfunction — alongside laboratory evidence of low testosterone.
A diagnosis of hypogonadism is not made on lab values alone. Symptoms matter. Context matters. And the type of hypogonadism matters.
The Endocrine Society and American Urological Association both emphasize that a complete evaluation of testosterone deficiency requires more than a single total testosterone measurement. It requires understanding why testosterone is low — and that begins with understanding how testosterone production is regulated.
The HPG Axis: Understanding the Body’s Testosterone Signaling System
Testosterone production operates through an elegantly regulated feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis. Understanding this system makes the distinction between primary and secondary hypogonadism immediately intuitive.
The process works like this:
- The hypothalamus (a region of the brain) releases gonadotropin-releasing hormone (GnRH) in pulsatile bursts.
- GnRH signals the pituitary gland to release two hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
- LH travels to the testes and signals the Leydig cells to produce testosterone. FSH stimulates sperm production.
- When testosterone levels are adequate, the hypothalamus and pituitary sense this and reduce their signaling — a classic negative feedback loop.
This system can fail at two distinct points: in the testes themselves, or in the brain’s signaling machinery. That failure point is what separates primary from secondary hypogonadism.
Primary Hypogonadism: When the Problem Is in the Testes
In primary hypogonadism, the testes are not producing adequate testosterone despite receiving appropriate signals from the brain. The pituitary is sending LH and FSH correctly — the testes simply are not responding as they should.
Because the brain senses low testosterone and tries to compensate, LH and FSH levels are typically elevated in primary hypogonadism. The brain is “shouting” louder, but the testes cannot respond.
Common Causes of Primary Hypogonadism
Primary hypogonadism can result from conditions that directly damage testicular tissue or impair its function:
- Klinefelter syndrome (47,XXY): The most common genetic cause of primary hypogonadism. Men carry an extra X chromosome, leading to smaller testes, impaired testosterone production, and often infertility. Many men are not diagnosed until adulthood.
- Mumps orchitis: Viral infection causing testicular inflammation. If it occurs after puberty, it can cause permanent damage to testosterone-producing cells.
- Testicular trauma or torsion: Physical injury or torsion-related ischemia can damage Leydig cells irreversibly.
- Chemotherapy and radiation: Gonadotoxic treatments used for cancer can cause primary testicular failure, sometimes permanently.
- Undescended testicles (cryptorchidism): When not corrected early, this condition may impair testicular function in adulthood.
- Autoimmune conditions: Rare cases of autoimmune testicular damage exist.
- Aging: The natural age-related decline in Leydig cell number and function contributes to lower testosterone over time, with a primary component in many older men.
In primary hypogonadism, the damage to the testes is generally structural or irreversible. This has important implications for treatment.
Secondary Hypogonadism: When the Problem Is in the Brain’s Signaling
In secondary hypogonadism — also called central or hypogonadotropic hypogonadism — testosterone is low because the hypothalamus or pituitary is not generating adequate LH and FSH signals. The testes themselves are often capable of functioning normally; they are simply not receiving the instruction to do so.
LH and FSH levels are typically low or inappropriately normal in secondary hypogonadism — not elevated as they would be in primary. The brain is not compensating because the problem is in the signaling pathway itself.
Common Causes of Secondary Hypogonadism
Secondary hypogonadism is the more clinically complex category, and critically, it is often partially or fully reversible:
- Obesity and insulin resistance: Excess body fat — particularly visceral adiposity — disrupts the HPG axis. Adipose tissue converts testosterone to estrogen via aromatase, suppresses GnRH pulsatility, and promotes insulin resistance. This is one of the most common causes of functional secondary hypogonadism seen in clinical practice today.
- Hyperprolactinemia: Elevated prolactin (from a pituitary adenoma or certain medications) suppresses GnRH release, impairing the entire HPG axis.
- Pituitary tumors or structural lesions: Space-occupying lesions can impair pituitary hormone secretion.
- Opioid use: Opioids powerfully suppress GnRH secretion. Even patients on chronic prescribed opioid therapy frequently develop secondary hypogonadism.
- Chronic illness: Conditions including type 2 diabetes, sleep apnea, hypothyroidism, inflammatory diseases, and liver disease all suppress the HPG axis through various mechanisms.
- Kallmann syndrome: A congenital condition causing GnRH deficiency, often presenting with absent or delayed puberty and anosmia.
- Anabolic steroid use: Exogenous androgens suppress the HPG axis. Axis suppression can persist for months to years after cessation.
- Significant psychological stress: Chronic stress and sleep deprivation both impair GnRH pulsatility.
In many cases of secondary hypogonadism, addressing the underlying cause — losing weight, treating sleep apnea, resolving hyperprolactinemia, discontinuing suppressive medications — can meaningfully improve testosterone levels without requiring direct replacement.
How Physicians Differentiate Between the Two
The critical laboratory distinction between primary and secondary hypogonadism lies in the gonadotropins: LH and FSH.
A complete testosterone evaluation at LiteWell includes:
- Total testosterone (ideally measured in the morning between 7–10 AM)
- Free testosterone (calculated or equilibrium dialysis)
- LH (luteinizing hormone)
- FSH (follicle-stimulating hormone)
- Prolactin (to screen for pituitary dysfunction)
- SHBG (sex hormone-binding globulin — affects free testosterone)
- Comprehensive metabolic panel, CBC, thyroid function (identify contributing conditions)
The interpretive pattern is straightforward:
- Low testosterone + high LH/FSH = Primary hypogonadism (the brain is compensating; the testes are failing to respond)
- Low testosterone + low or normal LH/FSH = Secondary hypogonadism (the brain’s signal is insufficient; the testes may be capable of more)
This single distinction — answering the question of what LH and FSH are doing — completely changes the clinical picture and the treatment roadmap.
Why the Distinction Matters for Treatment
This is where the clinical stakes become real.
Reversibility
Primary hypogonadism, by definition, involves damage or dysfunction of the testes themselves. Testosterone replacement therapy (TRT) is appropriate and effective, but it does not and cannot restore natural testicular function. The testes are structurally limited.
Secondary hypogonadism, by contrast, often involves a functional suppression of the HPG axis. When the underlying cause is identified and addressed — whether that is weight loss, treatment of sleep apnea, discontinuation of a suppressive medication, or management of hyperprolactinemia — natural testosterone production may improve substantially. In these situations, TRT is not always the first intervention; treating the cause is.
Fertility
This distinction is critical for men who wish to have biological children. TRT suppresses the HPG axis, dramatically reducing sperm production. For men with secondary hypogonadism who want fertility, there are alternatives:
- Human chorionic gonadotropin (hCG): Mimics LH, directly stimulating the testes to produce testosterone and supporting sperm production simultaneously.
- Clomiphene citrate: Blocks estrogen receptors in the hypothalamus, increasing GnRH and LH release — stimulating the axis rather than bypassing it.
- FSH therapy: Used in combination with hCG for men with low FSH who need sperm maturation support.
These stimulation approaches are appropriate for secondary hypogonadism because the testes retain the capacity to respond. In primary hypogonadism with significant testicular damage, the testes cannot meaningfully respond to stimulation.
Safety Monitoring
Both types require ongoing monitoring of hematocrit, PSA, lipids, and clinical symptoms. However, men with secondary hypogonadism also need ongoing evaluation of the underlying cause — periodic reassessment of prolactin, pituitary imaging where indicated, and thyroid and metabolic monitoring.
Myths vs. Facts
Myth: A single testosterone lab result is all you need to diagnose and treat low T.
Fact: A complete evaluation requires total and free testosterone, LH, FSH, and prolactin at minimum. Without LH and FSH, you don’t know why testosterone is low — and that determines treatment.
Myth: All men with low testosterone need TRT.
Fact: Many men with secondary hypogonadism have treatable underlying causes. Weight loss, sleep apnea treatment, medication changes, or management of thyroid disease may restore testosterone without direct replacement.
Myth: If LH and FSH are normal, testosterone must be fine.
Fact: In secondary hypogonadism, LH and FSH can appear “normal” when they are inappropriately low for the level of testosterone deficiency. Context and the full clinical picture matter.
Myth: Men with low testosterone on TRT can still have children easily.
Fact: TRT suppresses sperm production. Men who want to preserve fertility should discuss hCG-based or clomiphene-based approaches with their physician before starting TRT.
Myth: Secondary hypogonadism is less serious than primary.
Fact: Both cause the same range of clinical symptoms. Secondary hypogonadism is often more reversible, but it requires more thorough investigation to identify the underlying cause.
Myth: Testosterone testing is straightforward — just get your T checked.
Fact: Timing, technique, and the accompanying hormonal context all matter. A testosterone level drawn at 3 PM after poor sleep is not the same as a properly timed morning draw interpreted alongside LH, FSH, and SHBG.
LiteWell’s Clinical Approach
At LiteWell, we evaluate testosterone deficiency the way it deserves to be evaluated: comprehensively.
We do not prescribe TRT based on a single testosterone number. Before any treatment recommendation, we need to understand:
- Is the testosterone level truly low, properly timed and measured?
- Is there a primary testicular issue, or is the HPG axis the source of the problem?
- Are there reversible contributing factors — obesity, sleep apnea, medications, metabolic disease — that should be addressed first or alongside treatment?
- What does the patient’s fertility picture look like, and does that change the approach?
- What are the patient’s goals, timeline, and preferences?
Our Premier Discovery Intake is designed around exactly this kind of thorough evaluation. Patients meet directly with a LiteWell physician — not a nurse or a coordinator — who reviews the full lab panel, medical history, symptoms, and goals before any treatment plan is established.
For men with secondary hypogonadism, we often pursue a parallel approach: addressing underlying metabolic and lifestyle contributors while providing appropriate hormonal support. For men with primary hypogonadism, we develop a TRT protocol tailored to their clinical profile, with ongoing monitoring to ensure safety and efficacy.
The Free Medical Fit Call is a no-commitment opportunity to speak with our clinical team and understand whether you are a candidate for evaluation. It costs nothing, and it is how most LiteWell patients begin their journey.
You deserve a diagnosis that explains the why, not just the what. That is the standard we hold ourselves to.
Frequently Asked Questions
What is the most common type of hypogonadism in adult men?
Secondary hypogonadism is considerably more common in adult men, particularly in those who are middle-aged or older with metabolic syndrome, obesity, or insulin resistance. Functional secondary hypogonadism — where HPG axis suppression is driven by reversible factors — has become the predominant clinical presentation in modern practice. Primary hypogonadism is less common and usually associated with specific underlying conditions such as Klinefelter syndrome, prior chemotherapy or radiation, or testicular trauma.
Can you have both primary and secondary hypogonadism at the same time?
Yes. Mixed hypogonadism — sometimes called combined hypogonadism — occurs when both testicular dysfunction and impaired HPG axis signaling are present simultaneously. This is not uncommon in older men, who may have age-related testicular decline alongside metabolic or pituitary dysfunction. In these cases, LH and FSH may be only modestly elevated or may appear inappropriately normal, making interpretation more nuanced. A thorough physician evaluation is essential.
Will treating the underlying cause of secondary hypogonadism restore my testosterone to normal?
It depends on how long the suppression has persisted, how severe it is, and what is causing it. For men with relatively recent HPG axis suppression from obesity or sleep apnea, meaningful recovery is often possible with treatment. For men with chronic or severe secondary hypogonadism, partial recovery may occur, but TRT may still be appropriate. Individual responses vary, and the goal is always to optimize health through the most appropriate combination of interventions.
What labs are required to determine which type of hypogonadism I have?
The essential labs are total testosterone (morning draw), free testosterone, LH, FSH, and prolactin. SHBG is also valuable because it affects how much testosterone is biologically available. Comprehensive metabolic panel, CBC, thyroid function, and HbA1c are typically included to screen for contributing conditions. In some cases, additional imaging (pituitary MRI) or genetic testing (karyotype for suspected Klinefelter) may be warranted.
Does secondary hypogonadism always mean something is wrong with my pituitary?
Not at all. The majority of secondary hypogonadism cases are functional — meaning the HPG axis is being suppressed by external or systemic factors rather than by structural pituitary disease. Obesity, poor sleep, opioid use, chronic illness, and significant psychological stress are among the most common drivers. Structural pituitary causes — tumors, infarction, surgical injury — are less common but important to rule out, particularly when prolactin is elevated or testosterone deficiency is severe.
I want to have children. Does my type of hypogonadism change my options?
Significantly. Men with secondary hypogonadism who want biological children are typically candidates for stimulation-based approaches — hCG, clomiphene citrate, or FSH therapy — that work with the HPG axis rather than bypassing it. These approaches can support both testosterone levels and sperm production simultaneously. Standard TRT suppresses sperm production and is generally not appropriate for men actively pursuing fertility. Men with primary hypogonadism and significant testicular damage have more limited fertility options, and referral to a reproductive urologist is often appropriate.
Can opioid use cause secondary hypogonadism even at prescribed doses?
Yes. Opioid-induced androgen deficiency (OPIAD) is well-documented and occurs at therapeutic doses, not only with misuse. Opioids suppress GnRH pulsatility in the hypothalamus, leading to reduced LH, FSH, and subsequently testosterone. The effect is dose-related and often develops within weeks of initiating chronic opioid therapy. Men on long-term opioid prescriptions should have their testosterone and gonadotropins periodically checked, particularly if they develop symptomatic hypogonadism.
Is secondary hypogonadism ever caused by a brain tumor?
Yes, though this is less common. Pituitary adenomas — benign pituitary tumors — are an important cause of secondary hypogonadism, particularly prolactin-secreting adenomas (prolactinomas). Elevated prolactin directly suppresses GnRH secretion. Other pituitary or hypothalamic tumors can impair gonadotropin secretion through mass effect. Elevated prolactin on labs always warrants further evaluation, which typically begins with pituitary MRI.
How does Klinefelter syndrome relate to hypogonadism, and how common is it?
Klinefelter syndrome (47,XXY) is the most common chromosomal cause of primary hypogonadism in men, occurring in approximately 1 in 500–650 male births. The extra X chromosome leads to smaller testes, impaired testosterone production, and typically azoospermia (absence of sperm). Many men with Klinefelter syndrome are not diagnosed until they present with infertility, delayed puberty, or symptoms of testosterone deficiency in adulthood. TRT is the appropriate treatment for the hormonal component.
What is the difference between hypogonadism and just having naturally low testosterone?
Hypogonadism refers to a clinical syndrome — the combination of low testosterone levels and symptoms attributable to that deficiency. Having a testosterone level below the laboratory reference range without symptoms does not meet the clinical criteria for hypogonadism requiring treatment. This is why symptom evaluation is as important as laboratory values. Some men are asymptomatic with levels that would cause significant symptoms in others. Treatment decisions are always individualized.
Can lifestyle changes alone fix secondary hypogonadism?
In some cases, yes — particularly when the underlying driver is obesity, poor sleep, or metabolic dysfunction. Weight loss has been shown to meaningfully increase testosterone in men with obesity-related secondary hypogonadism. Treating obstructive sleep apnea can also improve testosterone levels. The degree of recovery varies considerably between individuals, and for men with significant symptoms, a combined approach — lifestyle optimization alongside appropriate hormonal support — often produces the best outcomes.
How long does it take to see improvement after starting treatment for hypogonadism?
The timeline varies by treatment type and individual response. Men starting TRT often notice early improvements in energy and mood within 3–6 weeks, with more substantial changes in body composition, libido, and strength developing over 3–6 months. Men pursuing stimulation-based therapies for secondary hypogonadism typically see testosterone improvements over 4–12 weeks, though individual responses vary. Symptom resolution often lags behind laboratory normalization. Ongoing follow-up and dose adjustments are part of the process.
Related LiteWell Services
- Hormone Optimization
- Medical Weight Loss
- Longevity & Performance Medicine
- Free Medical Fit Call
- Premier Discovery Intake
Related Insights
- What Is TRT and Who Is It For? A Physician’s Plain-English Guide
- Morning Testosterone Draw: Why Timing Your Labs Matters
- Low Testosterone in Minneapolis: Why More Men Are Getting Answers at LiteWell
- The Role of LH, FSH, and Prolactin in a Complete Hormone Workup
- Testosterone and Fertility: What Men Need to Know Before Starting TRT
References
- Endocrine Society — Clinical Practice Guidelines on Testosterone Therapy in Men with Hypogonadism
- American Urological Association (AUA) — Guidelines on Testosterone Deficiency
- National Institutes of Health (NIH) — MedlinePlus: Hypogonadism
- U.S. Food and Drug Administration (FDA) — Guidance on Testosterone Products
- European Association of Urology (EAU) — Male Hypogonadism Guidelines
- American Society for Reproductive Medicine (ASRM) — Guidelines on Male Fertility and Hormonal Treatment
Medical Disclaimer
This article is intended for educational purposes only and should not be interpreted as personalized medical advice. Medical decisions should be made in consultation with a licensed healthcare professional who is familiar with your medical history. Treatment plans are individualized, and results vary. LiteWell does not provide emergency medical care.
Medication & Regulatory Disclosure
Testosterone replacement therapy (TRT) and related hormonal treatments discussed in this article are prescription medications available only through licensed physicians. Treatment decisions are always individualized and require a comprehensive clinical evaluation. Some compounded hormone preparations may not have undergone the same FDA approval process as commercially manufactured medications. LiteWell physicians discuss the full range of available options, including FDA-approved products, during the clinical evaluation process.
